Hiv 1 Infection Therapeutics
1. Agenerase patent expiration
Treatment: Treatment of hiv infection
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6730679 | GLAXOSMITHKLINE | Pharmaceutical formulations |
Nov, 2017
(8 years ago) | |
| US5723490 | GLAXOSMITHKLINE | THF-containing sulfonamide inhibitors of aspartyl protease |
Mar, 2015
(10 years ago) | |
| US5646180 | GLAXOSMITHKLINE | Treatment of the CNS effects of HIV |
Jul, 2014
(11 years ago) | |
| US5585397 | GLAXOSMITHKLINE | Sulfonamide inhibitors of aspartyl protease |
Dec, 2013
(12 years ago) | |
Drugs and Companies using AMPRENAVIR ingredient
Market Authorisation Date: 15 April, 1999
Dosage: CAPSULE; SOLUTION
More Information on Dosage
AGENERASE family patents
2. Apretude patent expiration
Treatment: NA
APRETUDE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(3 months from now) | |
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Feb, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12138264 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(5 years from now) | |
| US11224597 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 20 December, 2021
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
APRETUDE family patents
3. Aptivus patent
expiration
Treatment: Treatment of hiv-1 infection by the co-administration of tipranavir and ritonavir.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6147095 | BOEHRINGER INGELHEIM | Method for improving the pharmacokinetics of tipranavir |
Oct, 2019
(6 years ago) | |
| US6169181 | BOEHRINGER INGELHEIM | Compounds useful to treat retroviral infections |
May, 2014
(11 years ago) | |
|
US6169181 (Pediatric) | BOEHRINGER INGELHEIM | Compounds useful to treat retroviral infections |
Nov, 2014
(11 years ago) | |
|
US6147095 (Pediatric) | BOEHRINGER INGELHEIM | Method for improving the pharmacokinetics of tipranavir |
Apr, 2020
(5 years ago) | |
| US6231887 | BOEHRINGER INGELHEIM | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
Jul, 2018
(7 years ago) | |
| US5852195 | BOEHRINGER INGELHEIM | Pyranone compounds useful to treat retroviral infections |
Jun, 2019
(6 years ago) | |
|
US6231887 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
Jan, 2019
(6 years ago) | |
|
US5852195 (Pediatric) | BOEHRINGER INGELHEIM | Pyranone compounds useful to treat retroviral infections |
Dec, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Dec 23, 2011 |
Drugs and Companies using TIPRANAVIR ingredient
Market Authorisation Date: 23 June, 2008
Dosage: SOLUTION; CAPSULE
More Information on Dosage
APTIVUS family patents
4. Edurant patent expiration
Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive adult patients with hiv-1 rna less than or equal to 100,000 at the start of therapy
EDURANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101629 | JANSSEN PRODS | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug, 2022
(3 years ago) | |
| US7638522 | JANSSEN PRODS | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
Apr, 2023
(2 years ago) | |
| US6838464 | JANSSEN PRODS | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
Feb, 2021
(4 years ago) | |
| US7067522 | JANSSEN PRODS | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
Dec, 2019
(6 years ago) | |
| US8080551 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(2 years ago) | |
|
US7125879 (Pediatric) | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Oct, 2025
(2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
| M(M-223) | Feb 01, 2021 |
| New Patient Population(NPP) | Mar 15, 2027 |
| Pediatric Exclusivity(PED) | Sep 15, 2027 |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 15 September, 2026
Market Authorisation Date: 20 May, 2011
Dosage: TABLET
More Information on Dosage
EDURANT family patents
5. Emtriva patent expiration
Treatment: Treatment of hiv infection
EMTRIVA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5814639 (Pediatric) | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(9 years ago) | |
| US5814639 | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(10 years ago) | |
|
US6703396 (Pediatric) | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(4 years ago) | |
|
US6642245 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(4 years ago) | |
| US6642245 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(5 years ago) | |
| US6703396 | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(4 years ago) | |
| US5914331 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(8 years ago) | |
|
US5914331 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(8 years ago) | |
Drugs and Companies using EMTRICITABINE ingredient
Market Authorisation Date: 28 September, 2005
Dosage: SOLUTION; CAPSULE
How can I launch a generic of EMTRIVA before it's drug patent expiration?
More Information on Dosage
EMTRIVA family patents
6. Fuzeon patent expiration
Treatment: Treatment of hiv
FUZEON IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6133418 | ROCHE | Synthetic peptide inhibitors of HIV transmission |
Nov, 2014
(11 years ago) | |
| US6475491 | ROCHE | Treatment of HIV and other viral infections using combinatorial therapy |
Jun, 2015
(10 years ago) | |
| US5464933 | ROCHE | Synthetic peptide inhibitors of HIV transmission |
Jun, 2013
(12 years ago) | |
Drugs and Companies using ENFUVIRTIDE ingredient
Market Authorisation Date: 13 March, 2003
Dosage: INJECTABLE
More Information on Dosage
FUZEON family patents
7. Intelence patent expiration
Treatment: Treatment of hiv infection in combination with one or more additional hiv antiviral agents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7887845 | JANSSEN R AND D | Antiviral compositions |
Mar, 2019
(6 years ago) | |
|
US6878717 (Pediatric) | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
May, 2020
(5 years ago) | |
| US6878717 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Nov, 2019
(6 years ago) | |
| US8003789 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Nov, 2019
(6 years ago) | |
| US7037917 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Dec, 2020
(5 years ago) | |
|
US7037917 (Pediatric) | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Jun, 2021
(4 years ago) | |
|
US8003789 (Pediatric) | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
May, 2020
(5 years ago) | |
|
US7887845 (Pediatric) | JANSSEN R AND D | Antiviral compositions |
Sep, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 18, 2013 |
| New Patient Population(NPP) | Mar 26, 2015 |
| Pediatric Exclusivity(PED) | Jan 16, 2022 |
Drugs and Companies using ETRAVIRINE ingredient
NCE-1 date: 16 January, 2021
Market Authorisation Date: 26 March, 2012
Dosage: TABLET
More Information on Dosage
INTELENCE family patents
8. Isentress patent expiration
Treatment: Treatment of hiv infection
ISENTRESS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169780 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(2 years ago) | |
| US7754731 | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(3 years from now) | |
| US8771733 | MSD SUB MERCK | Pharmaceutical composition containing an anti-nucleating agent |
Jun, 2030
(4 years from now) | |
| US8852632 | MSD SUB MERCK | Pharmaceutical formulation containing a release rate controlling composition |
Jan, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7217713 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(3 years ago) | |
| US7435734 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(3 years ago) | |
|
US7217713 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(2 years ago) | |
| US7169780 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(2 years ago) | |
|
US7435734 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(2 years ago) | |
|
US7169780 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(1 year, 9 months ago) | |
|
US7754731 (Pediatric) | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Patient Population(NPP) | Nov 22, 2020 |
| M(M-114) | Mar 28, 2015 |
| New Dosing Schedule(D-167) | May 26, 2020 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 21 December, 2011
Dosage: TABLET, CHEWABLE; POWDER; TABLET
How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage
ISENTRESS family patents
9. Pifeltro patent expiration
Treatment: For use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current a...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8486975 | MSD MERCK CO | Non-nucleoside reverse transcriptase inhibitors |
Aug, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-827) | Sep 19, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2023 |
| New Patient Population(NPP) | Jan 27, 2025 |
Drugs and Companies using DORAVIRINE ingredient
NCE-1 date: 30 August, 2022
Market Authorisation Date: 30 August, 2018
Dosage: TABLET
More Information on Dosage
PIFELTRO family patents
10. Reyataz patent expiration
Treatment: Method for treating hiv-1 infection
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5849911 | BRISTOL MYERS SQUIBB | Antivirally active heterocyclic azahexane derivatives |
Jun, 2017
(8 years ago) | |
| US6087383 | BRISTOL MYERS SQUIBB | Bisulfate salt of HIV protease inhibitor |
Dec, 2018
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5849911 | BRISTOL MYERS SQUIBB | Antivirally active heterocyclic azahexane derivatives |
Jun, 2017
(8 years ago) | |
| US6087383 | BRISTOL MYERS SQUIBB | Bisulfate salt of HIV protease inhibitor |
Dec, 2018
(7 years ago) | |
|
US5849911 (Pediatric) | BRISTOL MYERS SQUIBB | Antivirally active heterocyclic azahexane derivatives |
Dec, 2017
(8 years ago) | |
|
US6087383 (Pediatric) | BRISTOL MYERS SQUIBB | Bisulfate salt of HIV protease inhibitor |
Jun, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-116) | Sep 30, 2011 |
| New Dosing Schedule(D-130) | Feb 04, 2014 |
| New Product(NP) | Jun 02, 2017 |
| New Patient Population(NPP) | Sep 24, 2018 |
| Pediatric Exclusivity(PED) | Mar 24, 2019 |
Drugs and Companies using ATAZANAVIR SULFATE ingredient
Market Authorisation Date: 20 June, 2003
Dosage: CAPSULE; POWDER
How can I launch a generic of REYATAZ before it's drug patent expiration?
More Information on Dosage
REYATAZ family patents
11. Rukobia patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8461333 | VIIV HLTHCARE | Salts of prodrugs of piperazine and substituted piperidine antiviral agents |
Feb, 2025
(10 months ago) | |
| US7745625 | VIIV HLTHCARE | Prodrugs of piperazine and substituted piperidine antiviral agents |
Nov, 2027
(1 year, 10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168615 | VIIV HLTHCARE | Prodrugs of piperazine and substituted piperidine antiviral agents |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2025 |
Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient
NCE-1 date: 02 July, 2024
Market Authorisation Date: 02 July, 2020
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
RUKOBIA family patents
12. Selzentry patent expiration
Treatment: Method of treating patients infected with ccr5-tropic hiv-1
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6667314 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Aug, 2021
(4 years ago) | |
| US6586430 | VIIV HLTHCARE | CCR5 modulators |
Dec, 2019
(6 years ago) | |
| US7576097 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
May, 2021
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6667314 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Aug, 2021
(4 years ago) | |
|
US7576097 (Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Nov, 2021
(4 years ago) | |
|
US7368460 (Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
May, 2023
(2 years ago) | |
| US6586430 | VIIV HLTHCARE | CCR5 modulators |
Dec, 2019
(6 years ago) | |
| US7368460 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Nov, 2022
(3 years ago) | |
| US7576097 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
May, 2021
(4 years ago) | |
|
US6667314 (Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Feb, 2022
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2012 |
| New Patient Population(NPP) | Oct 30, 2023 |
| New Product(NP) | Nov 04, 2019 |
| New Strength(NS) | Nov 04, 2019 |
| Pediatric Exclusivity(PED) | Apr 30, 2024 |
Drugs and Companies using MARAVIROC ingredient
NCE-1 date: 07 August, 2011
Market Authorisation Date: 04 November, 2016
Dosage: TABLET; SOLUTION
How can I launch a generic of SELZENTRY before it's drug patent expiration?
More Information on Dosage
SELZENTRY family patents
13. Sunlenca patent expiration
Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9951043 | GILEAD SCIENCES INC | Therapeutic compounds |
Feb, 2034
(8 years from now) | |
| US11267799 | GILEAD SCIENCES INC | Solid forms of an HIV capsid inhibitor |
Aug, 2038
(12 years from now) | |
| US10071985 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10654827 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(11 years from now) | |
| US11944611 | GILEAD SCIENCES INC | Capsid inhibitors for the treatment of HIV |
Aug, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2027 |
Drugs and Companies using LENACAPAVIR SODIUM ingredient
NCE-1 date: 22 December, 2026
Market Authorisation Date: 22 December, 2022
Dosage: SOLUTION; TABLET
More Information on Dosage
SUNLENCA family patents
14. Tivicay patent expiration
Treatment: NA
TIVICAY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(1 year, 8 months from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8129385 (Pediatric) | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(2 years from now) | |
|
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-166) | Jul 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Indication(I-758) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 09 June, 2016
Dosage: TABLET
How can I launch a generic of TIVICAY before it's drug patent expiration?
More Information on Dosage
TIVICAY family patents
15. Viread patent expiration
Treatment: Treatment of hiv infection in combination with one or more additional hiv antiviral agents; Treatment of hiv; Treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and olde...
VIREAD IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5977089 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(7 years ago) | |
|
US6043230 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(7 years ago) | |
|
US5922695 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(7 years ago) | |
|
US5935946 (Pediatric) | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jan, 2018
(7 years ago) | |
| US5977089 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(8 years ago) | |
| US5935946 | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jul, 2017
(8 years ago) | |
| US5922695 | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(8 years ago) | |
| US6043230 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-569) | Aug 11, 2011 |
| New Patient Population(NPP) | Aug 16, 2015 |
| Pediatric Exclusivity(PED) | Sep 24, 2017 |
| M(M-95) | Oct 01, 2013 |
| New Dosage Form(NDF) | Jan 18, 2015 |
| M(M-128) | Jul 24, 2016 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
Drugs and Companies using TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 18 January, 2012
Dosage: POWDER; TABLET
How can I launch a generic of VIREAD before it's drug patent expiration?
More Information on Dosage
VIREAD family patents
16. Vocabria patent expiration
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg
VOCABRIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Feb, 2031
(5 years from now) | |
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-273) | Jan 31, 2025 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR SODIUM ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Dosage: TABLET
More Information on Dosage
VOCABRIA family patents